Texas Oncology - Paris

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Lung cancer3 trials
• Triple-negative breast cancer2 trials
• Bladder cancer1 trial
• Cervical cancer1 trial
• Colorectal cancer1 trial
• Endometrial cancer1 trial
• Gastric and oesophageal cancer1 trial
• Head and neck cancer1 trial
• Kidney cancer1 trial
• Melanoma1 trial
• Metastatic breast cancer1 trial
• Ovarian cancer1 trial
• and 1 more

Phase

• Phase 34 trials
• Phase 11 trial

Status

• Active, not recruiting3 trials
• Completed2 trials

Lead sponsor

• Gilead Sciences1 trial
• NovoCure GmbH1 trial
• NRG Oncology1 trial
• Stemline Therapeutics, Inc.1 trial
• Tizona Therapeutics, Inc1 trial

Running trials

• Active, not recruiting

  Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT05089734· Phase 3· Gilead Sciences· Source

• Active, not recruiting

  TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

  NCT04485013· Phase 1· Tizona Therapeutics, Inc· Source

• Active, not recruiting

  Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967· Phase 3· NRG Oncology· Source

Closed trials

• Completed

  Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

  NCT03778931· Phase 3· Stemline Therapeutics, Inc.· Source

• Completed

  Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

  NCT02973789· Phase 3· NovoCure GmbH· Source